These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24972892)

  • 1. Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells.
    Wang XK; He JH; Xu JH; Ye S; Wang F; Zhang H; Huang ZC; To KK; Fu LW
    Cancer Res; 2014 Aug; 74(16):4431-45. PubMed ID: 24972892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
    Wang XK; To KK; Huang LY; Xu JH; Yang K; Wang F; Huang ZC; Ye S; Fu LW
    Oncotarget; 2014 Dec; 5(23):11971-85. PubMed ID: 25436978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
    Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
    Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling.
    Wang N; Wang Z; Peng C; You J; Shen J; Han S; Chen J
    Carcinogenesis; 2014 Nov; 35(11):2544-54. PubMed ID: 25194164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.
    Wang F; Mi YJ; Chen XG; Wu XP; Liu Z; Chen SP; Liang YJ; Cheng C; To KK; Fu LW
    Mol Med; 2012 Jul; 18(1):887-98. PubMed ID: 22549112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity.
    Huber S; Wege AK; Bernhardt G; Buschauer A; Brockhoff G
    Cytometry A; 2015 Aug; 87(8):707-16. PubMed ID: 25892097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
    Zhang GN; Zhang YK; Wang YJ; Gupta P; Ashby CR; Alqahtani S; Deng T; Bates SE; Kaddoumi A; Wurpel JND; Lei YX; Chen ZS
    Cancer Lett; 2018 Jun; 424():19-29. PubMed ID: 29518481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2.
    Zhao XQ; Dai CL; Ohnuma S; Liang YJ; Deng W; Chen JJ; Zeng MS; Ambudkar SV; Chen ZS; Fu LW
    Eur J Pharm Sci; 2013 Jun; 49(3):441-50. PubMed ID: 23619284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
    Shishido Y; Ueno S; Yamazaki R; Nagaoka M; Matsuzaki T
    Anticancer Res; 2013 Apr; 33(4):1379-86. PubMed ID: 23564776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
    Stewart CF; Leggas M; Schuetz JD; Panetta JC; Cheshire PJ; Peterson J; Daw N; Jenkins JJ; Gilbertson R; Germain GS; Harwood FC; Houghton PJ
    Cancer Res; 2004 Oct; 64(20):7491-9. PubMed ID: 15492275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic.
    Patrawala L; Calhoun T; Schneider-Broussard R; Zhou J; Claypool K; Tang DG
    Cancer Res; 2005 Jul; 65(14):6207-19. PubMed ID: 16024622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway.
    Wang Z; Wang N; Li W; Liu P; Chen Q; Situ H; Zhong S; Guo L; Lin Y; Shen J; Chen J
    Carcinogenesis; 2014 Oct; 35(10):2346-56. PubMed ID: 25085904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
    Liu T; Xu F; Du X; Lai D; Liu T; Zhao Y; Huang Q; Jiang L; Huang W; Cheng W; Liu Z
    Mol Cell Biochem; 2010 Jul; 340(1-2):265-73. PubMed ID: 20224986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
    Ma L; Liu T; Jin Y; Wei J; Yang Y; Zhang H
    Tumour Biol; 2016 Sep; 37(9):12889-12896. PubMed ID: 27449042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.
    McDowell HP; Meco D; Riccardi A; Tanno B; Berardi AC; Raschellà G; Riccardi R; Dominici C
    Int J Cancer; 2007 Mar; 120(5):1141-9. PubMed ID: 17131346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and ex vivo anti‑tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2‑overexpressing leukemia cells.
    Jing W; Zhou M; Chen R; Ye X; Li W; Su X; Luo J; Wang Z; Peng S
    Oncol Rep; 2021 Mar; 45(3):1142-1152. PubMed ID: 33650639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.